Cargando…
Synergistic MicroRNA Therapy in Liver Fibrotic Rat Using MRI‐Visible Nanocarrier Targeting Hepatic Stellate Cells
Liver fibrosis, as one of the leading causes of liver‐related morbidity and mortality, has no Food and Drug Administration (FDA)‐approved antifibrotic therapy yet. Although microRNA‐29b (miRNA‐29b) and microRNA‐122 (miRNA‐122) have great potential in treating liver fibrosis via regulating profibroti...
Autores principales: | Wu, Jun, Huang, Jinsheng, Kuang, Sichi, Chen, Jingbiao, Li, Xiaoxia, Chen, Bin, Wang, Jin, Cheng, Du, Shuai, Xintao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402399/ https://www.ncbi.nlm.nih.gov/pubmed/30886803 http://dx.doi.org/10.1002/advs.201801809 |
Ejemplares similares
-
Bimodal Imaging‐Visible Nanomedicine Integrating CXCR4 and VEGFa Genes Directs Synergistic Reendothelialization of Endothelial Progenitor Cells
por: Yu, Bingbo, et al.
Publicado: (2020) -
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment
por: Peng, Yuan, et al.
Publicado: (2018) -
Chitosan Based MicroRNA Nanocarriers
por: Genedy, Hussein H., et al.
Publicado: (2022) -
Inhibitory Effect of a Human MicroRNA, miR-6133-5p, on the Fibrotic Activity of Hepatic Stellate Cells in Culture
por: Hamada-Tsutsumi, Susumu, et al.
Publicado: (2020) -
Theranostic Nanomedicine for Synergistic Chemodynamic Therapy and Chemotherapy of Orthotopic Glioma
por: Tan, Junyi, et al.
Publicado: (2020)